Molecular diagnostics company KREATECH Inc, Durham, NC, will allow the Lung Cancer Mutation Consortium (LCMC) study sites to use its REPEAT-FREE™ POSEIDON™ Fluorescent In-Situ Hybridization (FISH) Probes to help identify molecular (DNA) changes in study samples.
The Consortium represents the largest initiative in the United States to prospectively examine non-small cell lung cancer tumors for molecular changes that have been linked with patient response to available therapies, according to the company.
The LCMC is providing critical genetic information on the biological profile of each patient’s tumor to allow
|The LCMC includes 16 leading cancer centers across the country. It is coordinated by a cross-institutional group of researchers and the National Lung Cancer Partnership. Find out more at www.golcmc.com and www.ClinicalTrials.gov.|
patients to join clinical trials directed at their particular tumor profile. As more and more cancer therapies become focused on particular tumor profiles, such information will increase the ability to test new therapies designed to improve outcomes for patients.
The company will supply its POSEIDON DNA FISH Probes to participating LCMC labs for testing genetic aberrations of ROS1, RET, ALK, and MET in the study. It will also provide technical support for the evaluation, validation, and clinical trial testing of the probes used in LCMC participating labs.